Antitumor effects of recombinant human interferon α-2a and hydroxyurea against chronic myelogenous leukemia

만성 골수성 백혈병에 대한 유전자 재조합 인터페론 α-2a와 hydroxyurea의 항암효과

  • Kim, Chang-hwan (Department Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University) ;
  • Lee, Beom-jun (Veterinary Public Health, College of Veterinary Medicine, Seoul National University) ;
  • Park, Jong-hwan (Department Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University) ;
  • Park, Jae-hak (Department Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University)
  • 김창환 (서울대학교 수의과대학 실험동물의학교실) ;
  • 이범준 (서울대학교 수의과대학 수의공중보건학교실) ;
  • 박종환 (서울대학교 수의과대학 실험동물의학교실) ;
  • 박재학 (서울대학교 수의과대학 실험동물의학교실)
  • Received : 2000.02.16
  • Published : 2000.03.25

Abstract

Prior to a clinical trial, the in vitro and in vivo antitumor effects of a new recombinant human interferon ${\alpha}-2a$ (rHu/IFN ${\alpha}-2a$) with/without hydroxyurea (HU) were investigated using chronic myelogenous leukemia (CML)-derived cell lines (K562 and KU812F) and BALB/c nude. mice transplanted with KU812F cells. The rHu/IFN ${\alpha}-2a$ ($10^4-10^6IU/ml$) strongly inhibited proliferation of both cell lines and the combined treatments with HU ($10{\mu}g/ml$) were more effective. In nude mice transplanted with KU812F cells. rHu/IFN ${\alpha}-2a(1{\times}10^6IU$) inhibited tumor growth by 42-65% at 15-21 days post-transplantation (DPT). The combined treatment of rHu/IFN ${\alpha}-2a (5{\times}10^5IU$) with HU (0.25mg/g b.w.) inhibited the tumor growth by 48-67% at 12-21 DPT. In addition, the treatment of rHu/IFN ${\alpha}-2a$ ($5{\times}10^6IU\;or\;1{\times}10^7IU$) rejected tumor transplantation by 40%. These results suggest that the new rHU/IFN ${\alpha}-2a$ alone or with HU is effective on CML cell lines.